Literature DB >> 27439623

Percutaneous Femoropopliteal Recanalization Using a Completely Transpedal/Transtibial Approach.

Timothy W I Clark1, Micah M Watts2, Tak W Kwan3.   

Abstract

PURPOSE: To report preliminary experience with femoropopliteal revascularization using a completely transpedal/transtibial approach.
MATERIALS AND METHODS: Three patients with Rutherford 3-4 disease underwent revascularization of TASC C/D lesions using a pedal/tibial artery as the only site of arterial access.
RESULTS: One patient with a chronic superficial femoral artery occlusion had continuity achieved to the common femoral artery using a dedicated reentry device and stenting; in a second patient, an occluded popliteal artery stent was successfully revised with an endograft; and in a third patient with morbid obesity, a chronic SFA occlusion was successfully stented. All patients experienced complete resolution of presenting symptoms; no puncture site complications were seen.
CONCLUSIONS: Use of a pedal/tibial approach as the sole site of arterial access may become an important access technique for femoropopliteal revascularization when patients have limited femoral access options.

Entities:  

Keywords:  Arterial access; Chronic total occlusions; Endovascular; Recanalization; Transpedal

Mesh:

Year:  2016        PMID: 27439623     DOI: 10.1007/s00270-016-1427-x

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  2 in total

Review 1.  Pharmacology of Peripheral Arterial Disease in the Angio Suite: What Every Interventionalist Should Know.

Authors:  Micah M Watts
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

2.  Transpedal approach for femoral-popliteal chronic total occlusions using the outback® elite re-entry device.

Authors:  Mike Gorenchtein; Naveed Rajper; Philip Green; Pankaj Khullar; Daniel Amoruso; Christian Franz Bulacan; Tak Kwan; Joseph Puma; Justin Ratcliffe
Journal:  CVIR Endovasc       Date:  2021-01-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.